Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791688 | 0.92 | NPSR1 (0.41) | IDO1NPSR1SIGMAR1DRD2MAPT | |
| Hydrochloric Acid SCHEMBL6792133 | 0.85 | ADORA2A (0.36) | MAPTKDM4EADORA2A | |
| SCHEMBL5228886 | 0.80 | CCNA2 (0.38) | NPSR1SIGMAR1DRD2MAPTBRD4 | |
| SCHEMBL6791964 | 0.74 | KDM4E (0.35) | NPSR1SIGMAR1DRD2MAPTBRD4 | |
| SCHEMBL6788219 | 0.73 | AURKA (0.52) | KDM4EMEN1KMT2APOLBADORA2A | |
| SCHEMBL6793980 | 0.72 | LATS1 (0.37) | NPSR1DRD2MAPTBRD4KDM4E | |
| SCHEMBL4148130 | 0.72 | CDK2 (0.57) | — | |
| SCHEMBL6792359 | 0.72 | CCNC (0.35) | NPSR1MAPTBRD4KDM4ERECQL | |
| SCHEMBL6791959 | 0.71 | DRD2 (0.37) | NPSR1SIGMAR1DRD2MAPTBRD4 | |
| Hydrochloric Acid SCHEMBL6793712 | 0.71 | CCNA2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | IDO1 2548/4885NPSR1 2809/4885SIGMAR1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.